Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184
ConditionHIV Infections
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorViiV Healthcare
About this trial
The purpose of the study is to assess the bioavailability, mass balance, pharmacokinetics, metabolism and excretion of radiolabeled (14C) VH4524184.
Eligibility criteria
Qualifiers
Willing and able to sign the Informed Consent Form (ICF).
Sex at birth: male or female; female participants must be of non-childbearing potential, or postmenopausal.
Age: 18 to 55 years, inclusive, at screening.
BMI: 18.0 to 32.0 kg/m², inclusive, at screening.
Disqualifiers
Employee of ICON, the Sponsor, GSK or associated vendors.
History of relevant drug and/or food allergies.
History of drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study drug.
Using tobacco/nicotine products within 60 days prior to the first study drug administration.
Trial design
Treatments tested in this trial
- VH4524184
- [14C]VH4524184 microdose
- [14C]VH4524184
Treatment groups
9 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov